ACR Journals On Air
When Can We Wean Remission Maintenance Therapy in Rheumatoid Arthritis?
Aug 6, 2024
Dr. Paul Emery, a renowned expert in rheumatology and early intervention for rheumatoid arthritis, discusses the complex process of tapering biologic therapies. He shares insights from his latest study on predicting flares, emphasizing the importance of individualizing treatment based on patient characteristics. The conversation highlights the evolution of remission strategies, patient-centric approaches, and the necessity of biomarker testing. Emery also touches on the role of mentorship in advancing rheumatology practices, showcasing the human side of patient care.
31:32
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Recent studies reveal that safe tapering of biologic therapy in rheumatoid arthritis is influenced by objective biomarkers and patient history.
- The importance of patient involvement in decision-making highlights the shift towards personalized treatment strategies in managing rheumatoid arthritis.
Deep dives
Evolution of Treatment for Rheumatoid Arthritis
The transition from viewing rheumatoid arthritis (RA) as a chronic and incurable condition to one where remission is achievable has been monumental in treatment. The advent of targeted therapy has led to a significant shift in how rheumatologists approach maintenance therapy, particularly regarding when it might be appropriate to wean patients off treatment. Historically, there was a general belief among practitioners that continuous therapy was necessary, but recent studies have explored the possibility of stopping therapy in patients who have achieved robust remission. Understanding which patients can safely taper their maintenance therapy is a critical question that continues to guide research and clinical practice.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
